1Y Close · As of Aug 26, 2026
SyntekaBio operates in the Publishing sector.
Legal name: SyntekaBio,Inc.
In fiscal year 2025, SyntekaBio (226330) reported revenue of 3.4 billion KRW, up 2736.7% from 121 million KRW a year earlier.
Operating profit was -10.8 billion KRW and net income was -17.4 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 29.8 billion KRW, with a P/B of 0.94.
These figures can be verified in the DART filing (receipt no. 20260319001402).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 3.4B | -10.8B | -17.4B |
| 2024 | 121M | -14.3B | -7.2B |
| 2023 | 123M | -12.3B | -11.4B |
Recent Filings
Other Business Matters (Voluntary Disclosure)
Material Event Report (Early CB Retirement Decision)
Semi-Annual Review Adverse Opinion (Capital Erosion 50%+ or Equity Below 1B)
Checks
2 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-27 | Other Business Matters (Voluntary Disclosure) |
| 2026-08-19 | Material Event Report (Early CB Retirement Decision) |
| 2026-08-14 | Semi-Annual Review Adverse Opinion (Capital Erosion 50%+ or Equity Below 1B) |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-04 | Officer/Major Shareholder Ownership Report |